Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Genmab (GMAB) stock was downgraded by Bernstein due to a looming patent cliff for Darzalex, a blood cancer drug marketed by ...
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...
Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results